The molecular mechanisms by which signaling via transforming growth factor-b (TGF-b) and interleukin 4 (IL-4) control the differentiation of CD4 + IL-9-producing helper T cells (T H 9 cells) remain incompletely understood. We found here that the DNA-binding inhibitor Id3 regulated T H 9 differentiation, as deletion of Id3 increased IL-9 production from CD4 + T cells. Mechanistically, TGF-b1 and IL-4 downregulated Id3 expression, and this process required the kinase TAK1. A reduction in Id3 expression enhanced binding of the transcription factors E2A and GATA-3 to the Il9 promoter region, which promoted Il9 transcription. Notably, Id3-mediated control of T H 9 differentiation regulated anti-tumor immunity in an experimental melanomabearing model in vivo and also in human CD4 + T cells in vitro. Thus, our study reveals a previously unrecognized TAK1-Id3-E2A-GATA-3 pathway that regulates T H 9 differentiation.
Naive CD4 + T cells differentiate into distinct subsets upon activation, including the T H 1, T H 2, T H 17 and regulatory T cell (T reg cell) subsets, after encountering antigen in different cytokine milieu microenvironments. Interleukin 9 (IL-9)-producing CD4 + helper T cells (T H 9 cells) 1 are induced from naive CD4 + T cells by transforming growth factor-β (TGF-β) together with IL-4 during stimulation of the T cell antigen receptor (TCR) in vitro 2, 3 . T H 9 cells have been shown to have roles in allergic inflammation [4] [5] [6] , autoimmune diseases 3, 7, 8 and cancer 9, 10 . Although the transcription factors STAT6 (refs. 2,11), GATA-3 (ref. 3), PU.1 (ref. 12 ) and IRF4 (ref. 6 ) are all reported to participate in the differentiation of T H 9 cells, the transcriptional networks that control T H 9 differentiation are not yet fully understood. In addition, the downstream molecular mechanisms by which TGF-β1 signals and IL-4 signals co-operatively drive the differentiation of T H 9 cells are not fully understood.
TGF-β1 mediates the differentiation of T reg cells or T H 17 cells depending on the absence of IL-6 or presence of IL-6, respectively [13] [14] [15] . Id3, a transcription factor that inhibits the binding of basic helix-loophelix proteins, such as E2A, to DNA can control the TGF-β1-mediated reciprocal differentiation of T reg cells and T H 17 cells in mice 16 . Moreover, Id3 deficiency increases IL-4 production and GATA-3 expression in T cells. Since T H 9 differentiation requires both TGF-β signaling and IL-4 signaling, we investigated if Id3 has a role in T H 9 differentiation.
Here we found that Id3 regulated T H 9 differentiation; deletion of Id3 increased the differentiation of naive CD4 + T cells into T H 9 cells.
Id3 expression in CD4 + T cells was downregulated by stimulation with TGF-β1 and IL-4, a process that required the kinase TAK1. A reduction in Id3 expression led to increased binding of the transcription factors E2A and GATA-3 at the Il9 promoter region, which resulted in increased Il9 transcription in naive CD4 + T cells in response to TGF-β1 and IL-4. Notably, Id3 controlled the anti-tumor immunity of T H 9 cells in an experimental tumor-bearing model in vivo, and IL-9 production was also regulated by Id3 in human CD4 + T cells as well. Collectively, our data reveal involvement of a previously unrecognized TAK1-Id3-E2A-GATA-3 pathway in the regulation of T H 9 differentiation.
RESULTS

Id3 deficiency increases IL-9 production in T cells in vitro
Null mutation of the gene encoding Id3 (Id3 −/− ) results in the defective generation of T reg cells from naive CD4 + T cells, largely due to uncontrolled IL-4 production by the Id3 −/− T cells 16 . Therefore, we investigated whether the Id3 deficiency might also cause increased IL-9 production in CD4 + T cells. For this, we obtained naive CD4 + CD25 − CD62L + T cells from wild-type or Id3 −/− mice 17 and cultured the cells with TGF-β1 and/or IL-4. We found that Id3deficient T cells had enhanced expression of Il9 mRNA and IL-9 protein in response to TGF-β1 plus IL-4, relative to that of their wildtype counterparts (Fig. 1a-c) . As expected, wild-type naive CD4 + T cells did not produce IL-9 after culture with TGF-β1 alone (Fig. 1b,d) . However, naive Id3 −/− T cells readily produced substantial amounts of 1 0 7 8 VOLUME 16 NUMBER 10 OCTOBER 2015 nature immunology A r t i c l e s IL-9 in response to TGF-β1 alone, without exogenous IL-4 ( Fig. 1b,d) . This was due to the rapid and substantial induction of endogenous IL-4 in the Id3 −/− T cells 16 , as neutralization of IL-4 with antibody to IL-4 (anti-IL-4) completely abrogated IL-9 production in these cells (Fig. 1b,d) .
We also studied Id3 f/f Cd4-Cre + mice, in which loxP-flanked Id3 alleles (Id3 f/f ) are deleted by Cre recombinase expressed from the T cell-specific Cd4 promoter (Cd4-Cre) specifically in T cells at the CD4 + CD8 + double-positive stage of thymocyte differentiation 18 . Naive CD4 + T cells from Id3 f/f Cd4-Cre + mice had expression of the activationassociated markers CD25 and CD69, as well as of Il2 mRNA, and apoptosis rates and T cell proliferation upon TCR stimulation similar to those of naive CD4 + T cells from control Id3 +/+ Cd4-Cre + mice ( Supplementary Fig. 1 ). However, naive CD4 + CD25 − T cells from Id3 f/f Cd4-Cre + mice differentiated substantially more into T H 9 cells than did CD4 + T cells from Id3 +/+ Cd4-Cre + mice, in response to TCR stimulation together with TGF-β1 alone or TGF-β1 plus IL-4 ( Fig. 1e) . Notably, we also acutely deleted Id3 in wild-type naive CD4 + T cells through the use of small interfering RNA (siRNA) and found enhanced expression of Il9 mRNA ( Fig. 1f ) and IL-9 protein ( Fig. 1g) after stimulation with TGF-β1 plus IL-4 in naive T cells in which Id3 was knocked down relative to that in T cells treated with control siRNA. These data demonstrated that loss of Id3 affected T H 9 differentiation.
TGF-b1 and IL-4 downregulate Id3
We next investigated whether signaling via TGF-β1 and IL-4 affected Id3 expression. Id3 mRNA expression can be regulated by TGF-β1 signaling 16 ; we found that the treatment of naive CD4 + T cells with TGF-β1 resulted in more Id3 mRNA during the first 1-3 h, followed by less Id3 mRNA by 12-24 h, relative to that of cells that underwent stimulation of the TCR alone (Fig. 1h) . The aforementioned regulation of Id3 expression by TGF-β was abolished in T cells deficient in either TGF-β receptor I (TGFβRI) or TGF-β receptor II (TGFβRII) (data not shown). When we quantified Id3 expression in naive CD4 + T cells, we found that Id3 expression was rapidly and significantly decreased at 1.5 h after stimulation with TGF-β1 plus IL-4, relative to that of cells that underwent stimulation of the TCR alone, and that this reduction lasted for at least 48 h ( Fig. 1h and data not shown). Furthermore, we observed the same degree of Id3 downregulation in cells treated with IL-4 alone ( Fig. 1h) . Thus, Id3 expression was downregulated by cytokine conditions that favor T H 9 differentiation.
TAK1 is required for Id3 downregulation downstream of TGF-b1
We then studied the molecular mechanisms underlying the TGF-β1-and/or IL-4-mediated downregulation of Id3 in CD4 + T cells. We used Tgfbr1 f/f Cd4-Cre + mice, which undergo deletion of loxP-flanked alleles encoding TGFβRI (Tgfbr1 f/f ) by Cd4-driven Cre, npg and Tgfbr2 f/f ER-Cre + mice, which undergo tamoxifen-induced deletion of loxP-flanked alleles encoding TGFβRII (Tgfbr2 f/f ) via Cre fused to a mutant ligand-binding domain of the estrogen receptor (ER-Cre) (which results in tamoxifen-dependent Cre recombinase activity), and thus lack expression of either TGFβRI or TGFβRII, respectively, in CD4 + T cells 19 , to investigate the requirement for TGF-β signaling in T H 9 differentiation. T cells that lacked either TGFβRI or TGFβRII failed to differentiate into T H 9 cells following stimulation with TGF-β1 plus IL-4 ( Fig. 2) but developed normally or even showed enhanced differentiation into interferon-γ (IFN-γ)-or IL-4-producing T cells, relative to their TGFβRI-or TGFβRIIsufficient counterparts ( Supplementary Fig. 2a and data not shown).
As expected, these TGFβR-deficient T cells failed to differentiate into Foxp3 + T reg cells or T H 17 cells ( Supplementary Fig. 2a and data not shown), which confirmed that TGF-β signaling was vital for T H 9 differentiation. Engagement of TGF-β1 with its cognate receptors activates signaling through pathways that involve members of the Smad family of signal transducers (Smad2, Smad3 and Smad4) and those that do not [20] [21] [22] . The canonical Smad-dependent signaling pathway is required for the generation of Foxp3 + T reg cells and T H 17 cells 19, 23 . Smad-dependent signaling is also important for T H 9 differentiation 24, 25 . Consistent with those observations, deletion of Smad2 (via deletion of loxP-flanked alleles encoding Smad2 by Cre expressed from the T cell-specific Lck promoter (Smad2 f/f Lck-Cre + )), Smad3 (Smad3 −/− ), Smad4 (via deletion of loxP-flanked alleles encoding Smad4 by Cd4-driven Cre (Smad4 f/f Cd4-Cre + )) or both Smad3 and Smad4 (Smad3 −/− Smad4 f/f Cd4-Cre + ) in T cells resulted in a partial decrease in their differentiation into T H 9 cells relative to that of their respective Smad-sufficient counterparts (Supplementary Fig. 2b-e ). However, Smad3 −/− Smad4 f/f Cd4-Cre + T cells did not downregulate Id3 following stimulation with TGF-β1 and IL-4 ( Supplementary  Fig. 2f ), which suggested that although the Smad-dependent pathway might have a role in IL-9 production in CD4 + T cells, it might not be directly associated with Id3.
Therefore, we investigated the Smad-independent pathways that regulate Id3 expression and IL-9 production. The TGF-β-activated kinase TAK1 is an important mediator of the TGF-β-triggered Smad-independent pathway 22, 26 . We treated naive CD4 + T cells from C57BL/6 mice with the TAK1 inhibitor 5z-7-oxozeaenol under T H 9-differentiation conditions and found that inhibition of TAK1 almost completely blocked the production of IL-9 by CD4 + T cells ( Fig. 3a-c and Supplementary Fig. 2b-e ). However, inhibition of TAK1 failed to substantially change in the differentiation of naive CD4 + Fig. 3a ), suggestive of a specific function for TAK1 in T H 9 differentiation. Because the TAK1 inhibitor we used can also inhibit other mitogen-activated protein kinases, we knocked down TAK1 via siRNA in naive CD4 + CD25 − CD62L + T cells from wildtype mice or by treating naive CD4 + T cells from Tak1 f/f ER-Cre + mice (which undergo tamoxifen-induced deletion of the loxP-flanked alleles encoding TAK1 (Map3k7 f/f ; called 'Tak1 f/f ' here) via ER-Cre) with 4-hydroxytamoxifen in vitro (Fig. 3d-f and Supplementary  Fig. 3b ). The reduction in TAK1 expression by these methods resulted in decreased IL-9 expression relative to that of naive CD4 + T cells treated with control siRNA or Tak1 f/f ER-Cre + naive CD4 + T cells treated with oil, respectively ( Fig. 3d-f ), without a change in the expression of mRNA encoding the transcription factor Foxp3 or IL-17 ( Supplementary Fig. 3b ); this indicated a specific role for TAK1 in T H 9 differentiation. Furthermore, treatment of naive Smad-deficient CD4 + T cells with a TAK1 inhibitor abolished their differentiation into T H 9 cells ( Supplementary Fig. 2b-e ). Signaling via the T cell costimulatory molecule OX40 is reported to amplify T H 9 differentiation 27 . We cultured naive CD4 + T cells from wild-type mice together with antigen-presenting cells from mice with transgenic expression of the ligand for OX40 and found that signaling via OX40 and its ligand indeed promoted their differentiation into T H 9 cells ( Supplementary Fig. 3c) . Notably, addition of the TAK1 inhibitor to the co-cultures significantly suppressed the frequency of IL-9 + cells after stimulation with TGF-β1 plus IL-4 compared with that of cells Fig. 3c ). This indicated a key role for TAK1-mediated signals in T H 9 differentiation. We then investigated whether TAK1 was involved in TGF-β1-and/ or IL-4-mediated inhibition of Id3 expression. The TAK1 inhibitor did not alter the Id3 suppression in CD4 + T cells stimulated with TGF-β1 plus IL-4 during the first 3-6 h in culture compared with that of cells not treated with the TAK1 inhibitor, but it completely reversed the suppression of Id3 expression by 24 h (Fig. 3g) . Treatment with the TAK1 inhibitor did not affect expression of the genes encoding IRF4 and PU.1 (Sfpi1), two transcription factors known to induce IL-9 expression 6, 12 (Supplementary Fig. 3d ), which suggested that these two molecules were not downstream of TAK1 during the induction of IL-9. These data suggested that TAK1 mediated the inhibition of Id3 during T H 9 differentiation.
T cells into T H 1 or T H 17 cells or inducible T reg cells (Supplementary
Loss of Id3 expression promotes Il9 transcription
We next investigated the molecular mechanisms by which loss of Id3 expression promoted T H 9 differentiation. We focused on the basic helix-loop-helix protein E2A, because Id3 forms a complex with E2A and prevents the binding of E2A to its target genes 28 and thus acts as an inhibitor of E2A. Therefore, we investigated whether the rapid and persistent reduction in Id3 expression induced by TGF-β1 and IL-4 might promote binding of E2A to the Il9 promoter and transcription of this gene. We knocked down E2A expression via siRNA in naive CD4 + T cells and stimulated them with TGF-β1 plus IL-4. We noted significant suppression of Il9 mRNA expression in naive CD4 + T cells transfected with E2A-specific siRNA compared with that of cells treated with control siRNA (Fig. 4a) . Conversely, ectopic expression of E47 (a splice variant of E2A) enhanced T H 9 differentiation (Supplementary Fig. 4a ). We measured Il9 promoter activity in response to TGF-β1 plus IL-4 by luciferase assay in CD4 + T cells transfected with E47-expressing or control vector and found that overexpression of E47 increased the activity of the Il9 promoter compared with its activity in cells transfected with control vector (Supplementary Fig. 4a) . These results suggested an important role for E2A in T H 9 differentiation. However, there was no substantial change in mRNA encoding E2A in naive CD4 + T cells stimulated with TGF-β1 plus IL-4 compared with that of cells stimulated via the TCR alone (Supplementary Fig. 4b) . Consistent with that, TGF-β1 plus IL-4 did not substantially affect E2A protein in naive CD4 + T cells (Supplementary Fig. 4c ), which suggested that the amount of E2A protein was not regulated via the induction of Il9 by TGF-β1 plus IL-4. We also investigated whether other members of the E-protein family, E2-2 and HEB, were involved in T H 9 differentiation. Knockdown of E2-2 or HEB did not substantially affect the induction of Il9 mRNA in CD4 + T cells (data not shown), which suggested a role specifically for E2A during T H 9 differentiation.
We next investigated whether the IL-9 production induced by TGF-β1 plus IL-4 was due to enrichment in the binding of E2A to the Il9 promoter. We also assessed the binding of GATA-3 to the Il9 promoter, since Id3 deficiency increases GATA-3 expression via an IL-4-dependent manner 16 . Although GATA-3 is reported to have a role in T H 9 differentiation 3 , the mechanisms by which GATA-3 controls IL-9 production remain elusive. Stimulation with TGF-β1 plus IL-4 resulted in significant upregulation of Gata3 expression in naive CD4 + T cells compared with that of cells stimulated via the TCR alone, at 24 h after stimulation, which corresponded to the induction of Il9 mRNA expression (P < 0.01 (Student's t-test); Supplementary  Fig. 5a ). Almost all of the IL-9 + CD4 + T cells also expressed GATA-3 protein (Supplementary Fig. 5b) . Analysis of the Il9 promoter with software that identifies transcription factor-binding sites revealed that the Il9 promoter contains at least two canonical E-proteinbinding elements (E-boxes), defined by the consensus nucleotide sequence CANNTG (where 'N' indicates any nucleotide) 28, 29 , located at positions +86 and −152 relative to the transcriptional start site, and at least one GATA-3-binding site at position −126 relative to the transcriptional start site (Fig. 4b) . Chromatin immunoprecipitation (ChIP) showed that binding of E2A to the Il9 promoter region was significantly enriched in wild-type T cells in response to TGF-β1 plus IL-4 compared with its binding in cells stimulated via the TCR alone (Fig. 4c) . GATA-3 showed enrichment at the Il9 promoter region in response to TGF-β1 plus IL-4 compared with its binding in cells stimulated via the TCR alone, as shown by ChIP ( Fig. 4d) and ChIP followed by deep sequencing (ChIP-Seq) (Fig. 4e) . The lack of Id3 in CD4 + T cells from Id3 −/− mice further enhanced the binding of E2A at the Il9 promoter relative to its binding in wild-type CD4 + T cells (Fig. 4c) .
To assess the direct function of the binding of E2A and GATA-3, we measured promoter activity by luciferase assay. We transfected wild-type Il9 or Il9 constructs with mutated E-boxes and/or GATA-3-binding sites into naive CD4 + T cells 16 and cultured the cells in the presence or absence of TGF-β1 plus IL-4 under TCR stimulation. As expected, the activity of the wild-type Il9 promoter construct increased following stimulation with TGF-β1 plus IL-4 ( Fig. 4f) , while the Il9 promoter containing mutated E-boxes or GATA-3 binding site showed lower activity compared with its activity in cells transfected with wild-type Il9 promoter construct, in response to TGF-β1 plus IL-4 ( Fig. 4f) ; this suggested that binding of E2A and GATA-3 to the Il9 promoter directly promoted transcription. Mutation of the E-boxes and the GATA-3-binding sites together suppressed most activation of the Il9 promoter compared with that of cells transfected with wild-type Il9 promoter construct (Fig. 4f) . These data indicated that binding of E2A and GATA-3 to the Il9 promoter promoted Il9 transcription independently but synergistically and that both regulatory activities were regulated by Id3.
Id3 deficiency increases anti-tumor responses in mice
We next investigated the regulatory function of Id3 in T H 9 differentiation in vivo. The frequency of T H 9 cells in the spleen, peripheral lymph nodes and lungs of 8-to 12-week-old Id3 −/− mice was almost two times greater than that of wild-type mice, in which the frequency of T H 9 cells was generally low (Supplementary Fig. 6a ). Id3 −/− mice had higher concentrations of IL-9 in the serum than did wild-type mice (Supplementary Fig. 6b ). We did not detect any greater frequency of IL-9-producing type 2 innate lymphoid cells 30 in Id3 −/− mice than in wild-type mice (data not shown).
We then investigated the role of Id3 in T H 9 cell-related pathology in vivo. T H 9 cells have been reported to inhibit tumor growth 9, 10 . To investigate whether Id3 deficiency increased the anti-tumor response of T cells, we used an experimental melanoma mouse model 9, 10 . To avoid potential nonspecific effects in Id3 −/− mice, which have defects in the thymic development of CD4 + T cells 16 , we used a T cell adoptive-transfer system. Because naive Id3 −/− CD4 + T cells 'preferentially' differentiated into T H 9 cells but not into T reg cells when stimulated via the TCR in the presence of TGF-β1 alone, we cultured Id3 −/− or wild-type naive CD4 + CD25 − T cells for 3 d with anti-CD3 and anti-CD28, together with TGF-β1, then injected the cells intravenously into Rag1 −/− mice (which have a congenital deficiency in mature B cells and T cells); we then subcutaneously injected B16 melanoma cells into the Rag1 −/− recipient mice. Mice that received Id3 −/− CD4 + T cells consistently showed slower tumor growth than that of mice that received wild-type CD4 + T cells; tumor size at day 15 in the mice that received Id3 −/− CD4 + T cells was almost half that of the mice that received wild-type CD4 + T cells ( Fig. 5 and data not shown) . Treatment with neutralizing antibody to IL-9 had no effect on tumor growth in tumorbearing mice that received wild-type CD4 + T cells compared with treatment with isotype-matched control antibody (Fig. 5a,b) , consistent with the absence of T H 9 cells in wild-type T cells treated with TGF-β1 alone (Fig. 1b,d) . However, treatment with anti-IL-9 significantly promoted melanoma growth in mice that received Id3 −/− CD4 + T cells compared with melanoma growth in their counterparts treated with isotype-matched control antibody (Fig. 5a,b) . Analysis of CD4 + T cells in the tumor and in the draining lymph nodes or spleen of mice that received Id3 −/− CD4 + T cells indicated that treatment with anti-IL-9 did not substantially change the frequency of IL-17 + T H 17 and Foxp3 + T reg cells and did not decrease (actually increased) the frequency of IFN-γ + T H 1 cells, compared with the frequency of these cells in mice not treated with anti-IL-9 ( Fig. 5c and data not shown); this suggested that the enhanced tumor growth in these anti-IL-9-treated mice was not due to a decrease in IFN-γ + T cells and/or an increase in T reg cells. 
A r t i c l e s
We also investigated the anti-tumor effect of Id3-deficient T H 9 cells from Id3 f/f Cd4-Cre + mice to exclude the possibility of an effect of the systemic Id3 deficiency of Id3 −/− mice on their thymic development. We adoptively transferred TGF-β1-treated naive CD4 + CD25 − T cells from Id3 f/f Cd4-Cre + mice or Id3 +/+ Cd4-Cre + mice into Rag1 −/− mice, followed by challenge of the recipient mice with melanoma cancer cells. Mice that received TGF-β1-treated naive Id3 f/f Cd4-Cre + T cells showed substantial suppression of the development and growth of tumors compared with their development and growth in mice that received TGF-β1-treated naive Id3 +/+ Cd4-Cre + T cells (Supplementary Fig. 7a ). The administration of anti-IL-9 completely abolished the anti-tumor effect of Id3 f/f Cd4-Cre + T cells, while it had no effect on the growth of tumors in mice given Id3 +/+ Cd4-Cre + T cells (Supplementary Fig. 7a) . These data indicated an important role for T H 9 cells differentiated from Id3-deficient CD4 + T cells in the suppression of melanoma tumor growth.
Because TAK1 was required for T H 9 differentiation in vitro, we next investigated whether TAK1 deficiency affected T H 9 cell-mediated anti-tumor immunity in vivo. We pre-stimulated TAK1-deficient or wild-type CD4 + T cells with TGF-β1 plus IL-4 in culture, then adoptively transferred the cells into Rag1 −/− mice, followed by challenge of the recipient mice with melanoma cancer cells. Rag1 −/− mice given TAK1-deficient CD4 + T cells had much faster tumor growth than that of mice given wild-type CD4 + T cells (Supplementary Fig. 7b ). We administered anti-IL-9 to the host mice every 3 d from day 0 to assess whether the anti-tumor immunity was indeed mediated by IL-9 in this setting. Blockade of IL-9 with anti-IL-9 promoted melanoma tumor-cell growth in the Rag1 −/− host mice given wild-type T cells compared with its growth in control antibody-treated Rag1 −/− mice given wild-type T cells ( Supplementary  Fig. 7b ), while it had no effect in the mice given TAK1-deficient CD4 + T cells (Supplementary Fig. 7b ). Analysis of intratumoral T cells showed no substantial difference in the frequency of IFN-γ + T cells or Foxp3 + T cells among TAK1-difficient T cells relative to their frequency among wild-type T cells (Supplementary Fig. 7d) . These data suggested that Id3 and TAK1 regulated the differentiation of T H 9 cells and their anti-tumor activity in vivo.
Id3 controls IL-9 production in human CD4 + T cells Finally, we investigated whether Id3 also had a regulatory role in the differentiation of human T H 9 cells. We isolated naive CD4 + CD25 − CD45RA + T cells from peripheral blood mononuclear cells of healthy human subjects and stimulated the cells with anti-CD3 α-IL-9
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Id3 +/+ Id3 alone or with anti-CD3 plus anti-CD28, in the presence of various stimuli. Similar to results obtained for mouse cells, TGF-β1 plus IL-4 induced the largest amount of Il9 mRNA (Fig. 6a) and IL-9 protein (Fig. 6b) under the condition of stimulation with anti-CD3 plus anti-CD28 compared with their abundance in cells in all other culture conditions, although TGF-β1 plus IL-4 also induced IL-9 under the condition of stimulation with anti-CD3 alone (Supplementary Fig. 8a) .
As seen in mouse T cells, the TAK1 inhibitor (5z-7-oxozeaenol) completely blocked the expression of Il9 mRNA and IL-9 protein induced by TGF-β1 plus IL-4 in human CD4 + T cells (Fig. 6a,b) , which suggested a critical role for TAK1 in the differentiation of human T H 9 cells. Consistent with results obtained for mouse cells, Id3 mRNA expression was much lower in human naive CD4 + T cells in response to TGF-β1 plus IL-4 than in response to stimulation via the TCR alone (Fig. 6c) , and this effect was reversed by treatment with the TAK1 inhibitor ( Fig. 6d) . Knockdown of Id3 expression by siRNA ( Supplementary  Fig. 8b) increased Il9 mRNA expression in human CD4 + T cells stimulated with TGF-β1 plus IL-4 ( Fig. 6e) . Thus, TAK1 was required for the differentiation of human T H 9 cells by inhibiting Id3 expression. Overall, these data showed that a TAK1-Id3-E2A-GATA-3 pathway modulated Il9 transcription in naive CD4 + T cells in response to stimulation with TGF-β1 and IL-4 ( Supplementary Fig. 9 ).
DISCUSSION
The molecular pathways responsible for T H 9 differentiation remain incompletely understood. In this paper, we found that Id3 negatively regulated IL-9 production in CD4 + T cells. First, deletion of Id3 resulted in significantly larger amounts of IL-9 in CD4 + T cells, and Id3 −/− naive CD4 + T cells readily produced IL-9 even when stimulated with TGF-β1 alone, due largely to the secretion of endogenous IL-4 from Id3 −/− T cells 16 . Second, the TGF-β1-and IL-4-induced downregulation of Id3 expression was key in promoting IL-9 production in T cells, and this required TAK1.
Id3 is critical for TGF-β1 signaling in T cells 16 . Id3 mRNA expression is reported to increase at early time points (< 3 h) after stimulation with TGF-β1, followed by a decrease at later time points 16 . Here, TGF-β1 plus IL-4 downregulated Id3 expression early during T cell stimulation in culture, and this downregulation lasted at least 48 h. Further analysis revealed that IL-4 alone also inhibited Id3 expression at early time points after stimulation (3 h) and that TGF-β1 signaling acted in a synergistic manner to downregulate Id3 at later time points (24 h). The molecular mechanism underlying the IL-4-mediated early downregulation of Id3 in CD4 + T cells remains unknown, but it appeared that this early decrease in Id3 expression alone was necessary but insufficient to promote T H 9 differentiation.
We found that blockade of TAK1 activity with an inhibitor completely reversed the downregulation of Id3 expression induced by TGF-β1 plus IL-4 and, notably, blocked the T H 9 differentiation of wild-type CD4 + T cells treated with a TAK1 inhibitor or with TAK1-specific siRNA, as well as in 4-hydroxytamoxifen-treated Tak1 f/f ER-Cre + CD4 + T cells. However, inhibition of TAK1 did not affect expression of the transcription factors IRF4 (ref. 6) and PU.1 (ref. 12) , which have been reported to control T H 9 differentiation. Smad2 and Smad4 have been shown to have a role in T H 9 cell differentiation 24, 25 . Here we expanded those findings and suggest a partial function for Smad2, Smad3 and Smad4 in T H 9 differentiation. However, inhibition of TAK1 almost completely abrogated T H 9 differentiation, which suggested a dominant role for the TAK1-dependent pathway in this process. Notably, blockade of TAK1 activity with a specific inhibitor also reduced IL-9 expression in Id3 −/− T cells (data not shown), which suggested that TAK1 might modulate IL-9 expression through additional Id3-independent pathways, such as pathways mediated by the transcription factor NF-κB 27 and/or members of the NFAT family of transcription factors 31 . These possibilities remain to be investigated. Nevertheless, downregulation of Id3 represents an important effector mechanism downstream of TAK1 during T H 9 differentiation.
The binding of E2A and GATA-3 to the Il9 promoter had a key role downstream of the reduction in Id3 expression during T H 9 differentiation. Downregulation of Id3 led to enhanced binding of E2A to the Il9 promoter, and multiple experimental approaches showed that binding of E2A and GATA-3 promoted Il9 transcription in CD4 + T cells. Although both GATA-3 expression and binding of E2A are known to be regulated by Id3 (refs. 16, 28) , these two factors seemed to have independent yet additive functions in Il9 activation, because mutation of the binding sites for both of these factors resulted in a synergetic and maximal reduction in Il9 transcription. In contrast to E2A, other E-proteins (E2-2 and HEB) seemed to be dispersible for Id3-mediated production of IL-9 by T cells.
We demonstrated the biological relevance of the regulation of T H 9 cells by Id3 in an experimental tumor model. Although T H 9 cells have been reported to be important in allergic inflammation 4-6 , autoimmune diseases 3,7,8 and tumor immunity 9,10 , the detection of T H 9 cells in vivo is rather difficult, as the generation and differentiation of T H 9 cells is transient 30, 32 . However, we identified an important role for T H 9 cells differentiated from Id3-deficient CD4 + T cells in the suppression of melanoma tumor growth in mice. This finding may have important implications for the consideration of Id3 as potential target for anti-tumor immunotherapy, as a reduction in or deletion of Id3 in T cells might drive them to differentiate into anti-tumor T H 9 cells rather than into T reg cells in response to relevant tumor antigens in the TGF-β-rich environment of tumors.
The observation that TAK1-deficient T cells did not produce IL-9 further strengthens the idea of a cross-talk between TAK and Id3 in T H 9 differentiation. Furthermore, we also demonstrated a role for TAK1 and Id3 in the differentiation of human T H 9 cells. Although the mechanistic details of how TAK1 signaling and Id3 signaling interact with each other remain to be elucidated, our findings provide further understanding of the molecular mechanisms by which TGF-β1 controls the differentiation of helper T cell subsets.
METHODS
Methods and any associated references are available in the online version of the paper. Accession codes. GEO: ChIP-seq analysis of GATA-3, GSE72051.
Note: Any Supplementary Information and Source Data files are available in the online version of the paper.
